Literaturliste 2006

More documents

Recommendations

Info

Glasmacher A, Metzger DRGs für Einsteiger (Buchrezension). Arzneimitteltherapie 2005, 23: 190 Glasmacher A, Naumann R. Konsensusgruppe der DGHO und ÖGHO mit Beiträgen von Blau I, Brück P, Gorschlüter, M, Hennemann B, Huhn D, Jost E, Kropff M, Moehler T, Scheid C, von Schilling C, Schmidt-Wolf, IGH. Empfehlungen zur Anwendung von Thalidomid bei Patienten mit einem multiplen Myelom. www.dgho.de, 13.02.2005; zweite Fassung: 20.07.2005 Glasmacher A, von Lilienfeld-Toal M, Schulte S, Hahn C, Schmidt-Wolf IGH, Prentice A. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin Microbiol Infect. 2005 Oct;11 Suppl 5:17-23. Review. Glasmacher A, Prentice A. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23-i32. Review. Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic, B, Schmidt-Wolf I. Misleading statements in a meta-analysis – Reply. Journal of Clinical Oncology 2005, 36: 9429-32 Glasmacher A, von Lilienfeld-Toal M. The current status of thalidomide in the management of multiple myeloma. Acta Haematol. 2005;114 Suppl 1:3-7. Review. Goh CS, Hodgson DR, Fearnside SM, Heller J, Malikides N. Sodium monofluoroacetate (Compound 1080) poisoning in dogs. Aust Vet J. 2005 Aug;83(8):474-9. Review. Gorschlüter M, Mey U, Glasmacher A, Schwerdtfeger R, Schmidt-Wolf IGH. Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum. Bone Marrow Transplant. 2005 Dec;36(12):1107. No abstract available. Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IGH, Sauerbruch T, Glasmacher A. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005 Jul;75(1):1-13. Review. Gressner O, Wasmuth HE, Lammert F. Gentests zur Einschätzung des Fibroserisikos bei chronischer Hepatitis C - Faktum oder Vision? Med Welt 2005; 56 (11): 490-494
Grünhage F, Sauerbruch T, Spengler U. [Tuberculosis--current therapeutic concepts] Dtsch Med Wochenschr. 2005 Jan 28;130(4):159-64. Review. German. Hartmann P, Lammertink J, Mansmann G, Hubel K, Salzberger B, Stutzer H, Engert A, Fätkenheuer G. A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. Eur J Med Res. 2005 Jan 28;10(1):29-35. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res. 2005 Nov-Dec;25(6C):4591-4. Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, Sauerbruch T. Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. Liver Int. 2005 Jun;25(3):657-66. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet. 2005 Aug;37(8):835-43 Homann N, Stickel F, Konig IR, Jacobs A, Junghanns K, Benesova M, Schuppan D, Himsel S, Zuber-Jerger I, Hellerbrand C, Ludwig D, Caselmann WH, Seitz HK. Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol-associated cancer in heavy drinkers. Int J Cancer. 2005 Nov 14; Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt- Wolf IGH, Abken H. A recombinant anti-CEA immunoreceptor with combined CD3zeta - CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut. 2005 Dec 2; Hoppe B, von Unruh G, Laube N, Hesse A, Sidhu H. Oxalate degrading bacteria: new treatment option for patients with primary and secondary hyperoxaluria? Urol Res. 2005 Nov;33(5):372-375. Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A. Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cystic fibrosis. Am J Kidney Dis. 2005 Sep;46(3):440-5.
Page 1 and 2: 14. Verzeichnis der Publikationen,
Page 3: Fätkenheuer G. [Entry inhibitors]
Page 7 and 8: Lammert F, Gressner AM, Ritter K, M
Page 9 and 10: Meissner, A, Lammert F, von Unruh G
Page 11 and 12: Pöge U, Gerhardt TM, Woitas RP. N-
Page 13 and 14: Siener R, Schade N, Nicolay C, von
Page 15: Weitzel T, Muhlberger N, Jelinek T,

Literaturliste 2006

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?